Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lenis d.o.o. - tropikamid - kapljice za oko, raztopina - tropikamid 10 mg / 1 ml - tropikamid

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

merck sharp & dohme, d.o.o. - betametazon; gentamicin - krema - betametazon 0,5 mg / 1 g  gentamicin1 mg / 1 g; gentamicin 1 mg / 1 g - betametazon in antibiotiki

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

merck sharp & dohme, d.o.o. - betametazon; gentamicin - mazilo - betametazon 0,5 mg / 1 g  gentamicin1 mg / 1 g; gentamicin 1 mg / 1 g - betametazon in antibiotiki

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

baxter d.o.o. - glicin; histidin; kalcijev klorid dihidrat; alanin; arginin; fenilalanin; izolevcin; levcin; metionin; prolin; serin; tirozin; treonin; triptofan; valin; magnezijev klorid heksahidrat; natrijev (s)-laktat; natrijev klorid; lizinijev klorid - raztopina za peritonealno dializo - glicin 0,51 g / 1000 ml  histidin0,714 g / 1000 ml  kalcijev klorid dihidrat0,184 g / 1000 ml  alanin0,951 g / 1000 ml  arginin1,071 g / 1000 ml  fenilalanin0,57 g / 1000 ml  izolevcin0,85 g / 1000 ml  levcin1,02 g / 1000 ml  metionin0,85 g / 1000 ml  prolin0,595 g / 1000 ml  serin0,51 g / 1000 ml  tirozin0,3 g / 1000 ml  treonin0,646 g / 1000 ml  triptofan0,27 g / 1000 ml  valin1,393 g / 1000 ml  magnezijev klorid heksahidrat0,051 g / 1000 ml  natrijev (s)-laktat4,48 g / 1000 ml  natrijev klorid5,38 g / 1000 ml  lizinijev klorid0,955 g / 1000 ml; histidin 0,714 g / 1000 ml  kalcijev klorid dihidrat0,184 g / 1000 ml  alanin0,951 g / 1000 ml  arginin1,071 g / 1000 ml  fenilalanin0,57 g / 1000 ml  izolevcin0,85 g / 1000 ml  levcin1,02 g / 1000 ml  metionin0,85 g / 1000 ml  prolin0,595 g / 1000 ml  serin0,51 g / 1000 ml  tirozin0,3 g / 1000 ml  treonin0,646 g / 1000 ml  triptofan0,27 g / 1000 ml  valin1,393 g / 1000 ml  magnezijev klorid heksahidrat0,051 g / 1000 ml  natrijev (s)-laktat4,48 g / 1000 ml  natrijev klorid5,38 g / 1000 ml  lizinijev klorid0,955 g / 1000 ml; kalcijev klorid dihidrat 0,184 g / 1000 ml  alanin0,951 g / 1000 ml  arginin1,071 g / 1000 ml  fenilalanin0,57 g / 1000 ml  izolevcin0,85 g / 1000 ml  levcin1,02 g / 1000 ml  metionin0,85 g / 1000 ml  prolin0,595 g / 1000 ml  serin0,51 g / 1000 ml  tirozin0,3 g / 1000 ml  treonin0,646 g / 1000 ml  triptofan0,27 g / 1000 ml  valin1,393 g / 1000 ml  magnezijev klorid heksahidrat0,051 g / 1000 ml  natrijev (s)-laktat4,48 g / 1000 ml  natrijev klorid5,38 g / 1000 ml  lizinijev klorid0,955 g / 1000 ml; alanin 0,951 g / 1000 ml  arginin1,071 g / 1000 ml  fenilalanin0,57 g / 1000 ml  izolevcin0,85 g / 1000 ml  levcin1,02 g / 1000 - hipertonične raztopine

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

baxter d.o.o. - glicin; histidin; kalcijev klorid dihidrat; alanin; arginin; fenilalanin; izolevcin; levcin; metionin; prolin; serin; tirozin; treonin; triptofan; valin; magnezijev klorid heksahidrat; natrijev (s)-laktat; natrijev klorid; lizinijev klorid - raztopina za peritonealno dializo - glicin 0,51 g / 1000 ml  histidin0,714 g / 1000 ml  kalcijev klorid dihidrat0,184 g / 1000 ml  alanin0,951 g / 1000 ml  arginin1,071 g / 1000 ml  fenilalanin0,57 g / 1000 ml  izolevcin0,85 g / 1000 ml  levcin1,02 g / 1000 ml  metionin0,85 g / 1000 ml  prolin0,595 g / 1000 ml  serin0,51 g / 1000 ml  tirozin0,3 g / 1000 ml  treonin0,646 g / 1000 ml  triptofan0,27 g / 1000 ml  valin1,393 g / 1000 ml  magnezijev klorid heksahidrat0,051 g / 1000 ml  natrijev (s)-laktat4,48 g / 1000 ml  natrijev klorid5,38 g / 1000 ml  lizinijev klorid0,955 g / 1000 ml; histidin 0,714 g / 1000 ml  kalcijev klorid dihidrat0,184 g / 1000 ml  alanin0,951 g / 1000 ml  arginin1,071 g / 1000 ml  fenilalanin0,57 g / 1000 ml  izolevcin0,85 g / 1000 ml  levcin1,02 g / 1000 ml  metionin0,85 g / 1000 ml  prolin0,595 g / 1000 ml  serin0,51 g / 1000 ml  tirozin0,3 g / 1000 ml  treonin0,646 g / 1000 ml  triptofan0,27 g / 1000 ml  valin1,393 g / 1000 ml  magnezijev klorid heksahidrat0,051 g / 1000 ml  natrijev (s)-laktat4,48 g / 1000 ml  natrijev klorid5,38 g / 1000 ml  lizinijev klorid0,955 g / 1000 ml; kalcijev klorid dihidrat 0,184 g / 1000 ml  alanin0,951 g / 1000 ml  arginin1,071 g / 1000 ml  fenilalanin0,57 g / 1000 ml  izolevcin0,85 g / 1000 ml  levcin1,02 g / 1000 ml  metionin0,85 g / 1000 ml  prolin0,595 g / 1000 ml  serin0,51 g / 1000 ml  tirozin0,3 g / 1000 ml  treonin0,646 g / 1000 ml  triptofan0,27 g / 1000 ml  valin1,393 g / 1000 ml  magnezijev klorid heksahidrat0,051 g / 1000 ml  natrijev (s)-laktat4,48 g / 1000 ml  natrijev klorid5,38 g / 1000 ml  lizinijev klorid0,955 g / 1000 ml; alanin 0,951 g / 1000 ml  arginin1,071 g / 1000 ml  fenilalanin0,57 g / 1000 ml  izolevcin0,85 g / 1000 ml  levcin1,02 g / 1000 - hipertonične raztopine

Evropska unija - slovenščina - EMA (European Medicines Agency)

janssen-cilag international nv - ustekinumab - psoriasis; arthritis, psoriatic; crohn disease; colitis, ulcerative - imunosupresivi - crohnova diseasestelara je indiciran za zdravljenje odraslih bolnikov z zmerno do hudo aktivno crohnovo boleznijo, ki so imeli neustreznega odziva, izgubil odgovor da, ali so bili nestrpni, da bodisi konvencionalne terapije ali tnfa antagonist ali imajo medicinske kontraindikacije za take terapije. ulcerozni colitisstelara je indiciran za zdravljenje odraslih bolnikov z zmerno do močno aktivnim ulceroznim kolitisom, ki so imeli neustreznega odziva, izgubil odgovor da, ali so bili nestrpni, da bodisi konvencionalne terapije ali biološkim ali imajo medicinske kontraindikacije za take terapije. plaketo psoriasisstelara je primerna za zdravljenje zmerno do hudo psoriazo v plakih pri odraslih, ki so se odzvali na ali ki so kontraindikacija za, ali so prenašali na druge sistemske terapije, vključno z ciclosporin, metotreksatom in psoralen ultravijolično a. pediatrični plaketo psoriasisstelara je primerna za zdravljenje zmerno do hudo psoriazo v plakih pri otrocih in mladostnikov bolnike, starejše od 6 let in več, ki so neustrezno nadzira, ali so nestrpni do druge sistemske terapije ali phototherapies. psoriatični arthritisstelara, samostojno ali v kombinaciji z metotreksatom, je primerna za zdravljenje aktivnega psoriatičnega artritisa pri odraslih bolnikih, kadar je odgovor na prejšnje ne-biološki bolezni spreminjajo antirheumatic drog (dmard) terapija je bila neustrezna.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artritis, revmatoidni - imunosupresivi - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 in 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, revmatoidni - imunosupresivi - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Evropska unija - slovenščina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hidroklorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imunosupresivi - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Evropska unija - slovenščina - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresivi - prosimo, glejte dokument o izdelku.